You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和譽(02256.HK)夥百濟神州(06160.HK)開展治療尿路上皮癌聯合臨牀研究
和譽(02256.HK)公佈,其附屬和譽醫藥在研的泛FGFR抑制劑ABSK091(AZD4547),將與百濟神州(06160.HK)自主研發的抗PD-1抗體替雷利珠單抗,開展針對尿路上皮癌聯合治療的臨牀研究。 ABSK091(AZD4547)是一種高效、選擇性的FGFR亞型FGFR1、2和3抑制劑。對多種FGFR基因改變腫瘤模型的研究顯示,其在體內的療效良好,具有很強的與其他靶向或免疫藥物結合的潛力。 和譽生物目前正在中國開展一項針對ABSK091(AZD4547)單藥治療尿路上皮癌的臨牀II期試驗,同時國內外多項臨牀試驗結果表明FGFR抑制劑與抗PD-1抗體聯用對尿路上皮癌效果顯着。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account